$CVSI
CV Sciences, Inc.

2020 Q4 Form 10-Q Financial Statement

#000151096420000077 Filed on November 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $5.199M $5.564M $12.60M
YoY Change -44.26% -55.85% -7.34%
Cost Of Revenue $2.978M $3.106M $4.175M
YoY Change -42.49% -25.6% 14.23%
Gross Profit $2.221M $2.458M $8.428M
YoY Change -46.48% -70.84% -15.26%
Gross Profit Margin 42.72% 44.18% 66.87%
Selling, General & Admin $11.41M $5.197M $8.657M
YoY Change 11.96% -39.97% 46.98%
% of Gross Profit 513.69% 211.43% 102.72%
Research & Development $412.0K $1.544M
YoY Change -73.32% 191.32%
% of Gross Profit 16.76% 18.32%
Depreciation & Amortization $243.0K $240.0K $179.0K
YoY Change 32.79% 34.08% 31.94%
% of Gross Profit 10.94% 9.76% 2.12%
Operating Expenses $11.69M $5.609M $10.20M
YoY Change 1.67% -45.02% 58.89%
Operating Profit -$9.464M -$3.151M -$1.773M
YoY Change 28.88% 77.72% -150.28%
Interest Expense -$9.000K -$6.000K $7.000K
YoY Change -169.23% -185.71% -122.91%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$9.473M -$3.157M -$1.766M
YoY Change 29.24% 78.77% -150.53%
Income Tax -$179.0K $0.00 $3.000K
% Of Pretax Income
Net Earnings -$9.294M -$3.157M -$1.769M
YoY Change 39.01% 78.46% -153.69%
Net Earnings / Revenue -178.77% -56.74% -14.04%
Basic Earnings Per Share -$0.03 -$0.02
Diluted Earnings Per Share -$92.79K -$0.03 -$0.02
COMMON SHARES
Basic Shares Outstanding 100.0M shares 99.95M shares 98.73M shares
Diluted Shares Outstanding 99.95M shares 98.73M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.024M $5.563M $13.74M
YoY Change -55.81% -59.51% 33.75%
Cash & Equivalents $4.024M $5.563M $13.74M
Short-Term Investments
Other Short-Term Assets $2.873M $8.639M $8.969M
YoY Change -74.15% -3.68% 246.91%
Inventory $8.840M $8.685M $10.03M
Prepaid Expenses $2.372M
Receivables $1.126M $1.318M $3.542M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $16.86M $24.21M $36.27M
YoY Change -47.9% -33.27% 72.1%
LONG-TERM ASSETS
Property, Plant & Equipment $2.877M $3.096M $3.454M
YoY Change -20.41% -10.36% 60.01%
Goodwill $2.788M $2.788M $2.788M
YoY Change 0.0% 0.0%
Intangibles $3.730M
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.310M $1.378M $1.227M
YoY Change -9.15% 12.31% 1.99%
Total Long-Term Assets $13.76M $14.20M $20.26M
YoY Change -32.27% -29.92% 103.46%
TOTAL ASSETS
Total Short-Term Assets $16.86M $24.21M $36.27M
Total Long-Term Assets $13.76M $14.20M $20.26M
Total Assets $30.63M $38.41M $56.54M
YoY Change -41.87% -32.07% 82.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.677M $1.647M $1.110M
YoY Change 3.71% 48.38% -4.72%
Accrued Expenses $9.805M $9.817M $10.37M
YoY Change -9.68% -5.3% 473.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.174M $363.0K
YoY Change
Total Short-Term Liabilities $14.34M $12.52M $12.15M
YoY Change 8.64% 3.05% 308.41%
LONG-TERM LIABILITIES
Long-Term Debt $1.453M $2.543M $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $298.0K
YoY Change -100.0% -100.0% -75.86%
Total Long-Term Liabilities $1.453M $0.00 $298.0K
YoY Change 257.88% -100.0% -75.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.34M $12.52M $12.15M
Total Long-Term Liabilities $1.453M $0.00 $298.0K
Total Liabilities $19.41M $18.96M $23.30M
YoY Change -17.53% -18.63% 340.95%
SHAREHOLDERS EQUITY
Retained Earnings -$63.92M -$54.63M -$34.95M
YoY Change 53.52% 56.3%
Common Stock $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.21M $19.45M $33.24M
YoY Change
Total Liabilities & Shareholders Equity $30.63M $38.41M $56.54M
YoY Change -41.87% -32.07% 82.16%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$9.294M -$3.157M -$1.769M
YoY Change 39.01% 78.46% -153.69%
Depreciation, Depletion And Amortization $243.0K $240.0K $179.0K
YoY Change 32.79% 34.08% 31.94%
Cash From Operating Activities -$1.468M -$1.728M -$1.058M
YoY Change -68.27% 63.33% -123.22%
INVESTING ACTIVITIES
Capital Expenditures -$263.0K -$288.0K -$397.0K
YoY Change 6.91% -27.46% 175.03%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$263.0K -$288.0K -$397.0K
YoY Change 6.91% -27.46% 175.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 192.0K 3.000K -44.00K
YoY Change -20.66% -106.82% -93.05%
NET CHANGE
Cash From Operating Activities -1.468M -1.728M -1.058M
Cash From Investing Activities -263.0K -288.0K -397.0K
Cash From Financing Activities 192.0K 3.000K -44.00K
Net Change In Cash -1.539M -2.013M -1.499M
YoY Change -66.76% 34.29% -139.67%
FREE CASH FLOW
Cash From Operating Activities -$1.468M -$1.728M -$1.058M
Capital Expenditures -$263.0K -$288.0K -$397.0K
Free Cash Flow -$1.205M -$1.440M -$661.0K
YoY Change -72.49% 117.85% -114.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001510964
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Entity Shell Company
EntityShellCompany
false
dei Entity File Number
EntityFileNumber
000-54677
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
CV Sciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
80-0944970
dei Entity Address Address Line1
EntityAddressAddressLine1
10070 Barnes Canyon Road
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
866
dei Local Phone Number
LocalPhoneNumber
290-2157
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
100018514 shares
CY2020Q3 us-gaap Cash
Cash
5563000 USD
CY2019Q4 us-gaap Cash
Cash
9107000 USD
CY2020Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
501000 USD
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
501000 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1318000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2177000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
8685000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
9971000 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8138000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10611000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
24205000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
32367000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3096000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3615000 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3199000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8709000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3739000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3766000 USD
CY2020Q3 us-gaap Goodwill
Goodwill
2788000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
2788000 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1378000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1442000 USD
CY2020Q3 us-gaap Assets
Assets
38405000 USD
CY2019Q4 us-gaap Assets
Assets
52687000 USD
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1647000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1617000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9817000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10856000 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
688000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
723000 USD
CY2020Q3 us-gaap Notes Payable Current
NotesPayableCurrent
363000 USD
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12515000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13196000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3635000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9517000 USD
CY2020Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
2543000 USD
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
0 USD
CY2020Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
263000 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
421000 USD
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
406000 USD
CY2020Q3 us-gaap Liabilities
Liabilities
18956000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
23540000 USD
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000 shares
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000 shares
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
190000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
190000000 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
100029000 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100029000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
99416000 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
99416000 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
10000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
10000 USD
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
74066000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
70774000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54627000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41637000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
19449000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
29147000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38405000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
52687000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5564000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12603000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19230000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
44368000 USD
CY2020Q3 us-gaap Cost Of Revenue
CostOfRevenue
3106000 USD
CY2019Q3 us-gaap Cost Of Revenue
CostOfRevenue
4175000 USD
us-gaap Cost Of Revenue
CostOfRevenue
10442000 USD
us-gaap Cost Of Revenue
CostOfRevenue
13430000 USD
CY2020Q3 us-gaap Gross Profit
GrossProfit
2458000 USD
CY2019Q3 us-gaap Gross Profit
GrossProfit
8428000 USD
us-gaap Gross Profit
GrossProfit
8788000 USD
us-gaap Gross Profit
GrossProfit
30938000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
412000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1544000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2667000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4574000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5197000 USD
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8657000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
19249000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36261000 USD
CY2020Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
5609000 USD
CY2019Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
10201000 USD
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
99950000 shares
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
21916000 USD
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
40835000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3151000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1773000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-13128000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-9897000 USD
CY2020Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-6000 USD
CY2019Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
7000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
0 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3157000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1766000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13128000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9895000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-138000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-3157000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-1769000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12990000 USD
us-gaap Net Income Loss
NetIncomeLoss
-9924000 USD
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
98733000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
99831000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
97524000 shares
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
29147000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
161000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1258000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5152000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
25414000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1243000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4681000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
21988000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
615000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-3157000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
19449000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
30116000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
197000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2091000 USD
CY2019Q1 cvsi Adjustmentsto Additional Paidin Capital Sharebased Compensation Employment Settlement
AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationEmploymentSettlement
7857000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-9384000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
30877000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
57000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2125000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
1229000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
34288000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
699000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-1769000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
33243000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12990000 USD
us-gaap Net Income Loss
NetIncomeLoss
-9924000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
629000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
533000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3116000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
4915000 USD
cvsi Stockbased Compensation Employment Settlement
StockbasedCompensationEmploymentSettlement
0 USD
cvsi Stockbased Compensation Employment Settlement
StockbasedCompensationEmploymentSettlement
7857000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-176000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
cvsi Noncash Lease Expense
NoncashLeaseExpense
455000 USD
cvsi Noncash Lease Expense
NoncashLeaseExpense
497000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
158000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
0 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
240000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
38000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-717000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
240000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1858000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1475000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2640000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
659000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2515000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
857000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5832000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2399000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
794000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
901000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-794000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-901000 USD
us-gaap Proceeds From Unsecured Notes Payable
ProceedsFromUnsecuredNotesPayable
2906000 USD
us-gaap Proceeds From Unsecured Notes Payable
ProceedsFromUnsecuredNotesPayable
0 USD
us-gaap Repayments Of Unsecured Debt
RepaymentsOfUnsecuredDebt
0 USD
us-gaap Repayments Of Unsecured Debt
RepaymentsOfUnsecuredDebt
474000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-195000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
176000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
279000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3082000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3544000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1303000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9608000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12935000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6064000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14238000 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Interest Paid Net
InterestPaidNet
9000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
18000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
70000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
239000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
21000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5405000 USD
cvsi Right Of Use Asset Foregone In Exchange For Reduction In Operating Lease Liability
RightOfUseAssetForegoneInExchangeForReductionInOperatingLeaseLiability
-4704000 USD
cvsi Right Of Use Asset Foregone In Exchange For Reduction In Operating Lease Liability
RightOfUseAssetForegoneInExchangeForReductionInOperatingLeaseLiability
0 USD
cvsi Sale Of Property And Equipment In Exchange For Prepaid Expenses And Other And Inventory
SaleOfPropertyAndEquipmentInExchangeForPrepaidExpensesAndOtherAndInventory
675000 USD
cvsi Sale Of Property And Equipment In Exchange For Prepaid Expenses And Other And Inventory
SaleOfPropertyAndEquipmentInExchangeForPrepaidExpensesAndOtherAndInventory
0 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2 segment
us-gaap Use Of Estimates
UseOfEstimates
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results may differ from these estimates. Significant estimates include the valuation of intangible assets, inputs for valuing equity awards, valuation of inventory, assumptions related to revenue recognition and the allowance for doubtful accounts.</span>
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5563000 USD
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13738000 USD
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
501000 USD
CY2019Q3 us-gaap Restricted Cash
RestrictedCash
500000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6064000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14238000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5564000 USD
CY2020Q3 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1.000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12603000 USD
CY2019Q3 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1.000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19230000 USD
us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1.000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
44368000 USD
us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1.000
CY2020Q2 us-gaap Proceeds From Unsecured Notes Payable
ProceedsFromUnsecuredNotesPayable
2900000 USD
CY2020Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
4889000 USD
CY2019Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4503000 USD
CY2020Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
797000 USD
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
415000 USD
CY2020Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2999000 USD
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5053000 USD
CY2020Q3 us-gaap Inventory Gross
InventoryGross
8685000 USD
CY2019Q4 us-gaap Inventory Gross
InventoryGross
9971000 USD
CY2020Q3 us-gaap Inventory Write Down
InventoryWriteDown
100000 USD
us-gaap Inventory Write Down
InventoryWriteDown
400000 USD
CY2019Q3 us-gaap Inventory Write Down
InventoryWriteDown
0 USD
us-gaap Inventory Write Down
InventoryWriteDown
0 USD
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8634000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8787000 USD
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1183000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2069000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9817000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10856000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3907000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
168000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3739000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3907000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
141000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3766000 USD
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3400000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.329
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.060
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.329
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.123
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.004
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.005
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.023
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M6D
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M13D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y3M25D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.47
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.16
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.36
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.83
cvsi Sharebased Compensation Arrangementby Sharebased Payment Award Numberof Peers Includedin Calculationof Expected Volatility
SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofPeersIncludedinCalculationofExpectedVolatility
5 company
CY2019Q3 cvsi Sharebased Compensation Arrangementby Sharebased Payment Award Numberof Peers Includedin Calculationof Expected Volatility
SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofPeersIncludedinCalculationofExpectedVolatility
5 company
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26155000 shares
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25890000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26155000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25890000 shares
cvsi Number Of Shareholder Derivative Suits
NumberOfShareholderDerivativeSuits
4 lawsuit
cvsi Number Of Shareholder Derivative Suits Stayed
NumberOfShareholderDerivativeSuitsStayed
4 leaseTerminationAgreement
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2 segment
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5564000 USD
CY2020Q3 us-gaap Gross Profit
GrossProfit
2458000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
412000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5197000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3151000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12603000 USD
CY2019Q3 us-gaap Gross Profit
GrossProfit
8428000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1544000 USD
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8657000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1773000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19230000 USD
us-gaap Gross Profit
GrossProfit
8788000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2667000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
19249000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-13128000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
44368000 USD
us-gaap Gross Profit
GrossProfit
30938000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4574000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36261000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-9897000 USD
cvsi Net Operating Loss Tax Benefit Recognized
NetOperatingLossTaxBenefitRecognized
0 USD
cvsi Net Operating Loss Tax Benefit Recognized
NetOperatingLossTaxBenefitRecognized
0 USD
cvsi Employee Portion Of Payroll Taxes Paid
EmployeePortionOfPayrollTaxesPaid
200000 USD

Files In Submission

Name View Source Status
0001510964-20-000077-index-headers.html Edgar Link pending
0001510964-20-000077-index.html Edgar Link pending
0001510964-20-000077.txt Edgar Link pending
0001510964-20-000077-xbrl.zip Edgar Link pending
cvsi-20200930.htm Edgar Link pending
cvsi-20200930.xsd Edgar Link pending
cvsi-20200930xex311ng.htm Edgar Link pending
cvsi-20200930xex312ng.htm Edgar Link pending
cvsi-20200930xex321ng.htm Edgar Link pending
cvsi-20200930xex322ng.htm Edgar Link pending
cvsi-20200930_cal.xml Edgar Link unprocessable
cvsi-20200930_def.xml Edgar Link unprocessable
cvsi-20200930_htm.xml Edgar Link completed
cvsi-20200930_lab.xml Edgar Link unprocessable
cvsi-20200930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending